Recurrent Shingles (Herpes Zoster): Risk Factors, Immunology, and Prevention

Recurrent herpes zoster (shingles) occurs in 1–6% of immunocompetent individuals but is significantly more common with immunosuppression. A third episode is unusual and warrants immune evaluation.

Risk Factors for Recurrence

• Immunosuppression: HIV/AIDS (CD4 <200), hematologic malignancy, solid organ transplant, immunosuppressive therapy (anti-TNF, corticosteroids >20 mg prednisone/day), chemotherapy.
• Age: Immunosenescence; risk ↑ after 50.
• Severe Initial Episode: Postherpetic neuralgia (PHN), disseminated zoster, ophthalmic involvement.
• Female Sex: Slightly higher recurrence risk.
• Comorbidities: Diabetes, CKD, autoimmune diseases (SLE, RA).

Immunological Basis

VZV latency in dorsal root ganglia. Reactivation controlled by VZV-specific CD4+ and CD8+ T-cells. Recurrence = failure of immune surveillance.

Evaluation for Recurrent Zoster

• HIV test (if not known).
• CBC with differential, immunoglobulins (IgG subclasses).
• Lymphocyte subsets (CD4/CD8) if clinically indicated.
• Medication review (immunosuppressants).
• Age-appropriate cancer screening.

Prevention: Recombinant Zoster Vaccine (RZV, Shingrix)

• >90% efficacy in preventing zoster and PHN across age groups.
• 2 doses, 2–6 months apart. Recommended for all ≥50 years AND immunocompromised ≥19 years.
• Can be given after zoster episode (wait until acute phase resolved).
• Superior to live ZVL (Zostavax – discontinued US).

Management of Acute Recurrence

• Antivirals (valacyclovir 1g TID × 7 days) – start within 72 hrs of rash.
• Pain management (gabapentinoids, TCAs, opioids if severe).
• Corticosteroids controversial – may reduce acute pain but not PHN; avoid in immunocompromised.

Three episodes is a sentinel event. Comprehensive immune assessment is warranted.